NCT05551936 2026-02-17A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular LymphomaBig Ten Cancer Research ConsortiumPhase 1/2 Active not recruiting42 enrolled
NCT03997968 2024-12-24A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid TumorsCyteir Therapeutics, Inc.Phase 1/2 Completed169 enrolled
NCT02596971 2021-05-24A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)Hoffmann-La RochePhase 1/2 Completed91 enrolled 27 charts
NCT00987493 2019-05-15Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell LymphomaSwiss Cancer InstitutePhase 1/2 Completed49 enrolled
NCT02134262 2014-11-06Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T LymphocytesJichi Medical UniversityPhase 1/2 Unknown18 enrolled
NCT01238146 2013-06-06Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1/2 Withdrawn